St Jude Medical has completed the acquisition of AGA Medical, a developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders.
The acquisition of AGA Medical adds to St Jude Medical‘s portfolio in four new markets – the market for left atrial appendage (LAA) closure, the market for patent foramen ovale (PFO) closure, the market to modify abnormal peripheral vessels with vascular plugs and the market to repair structural heart defects.
The AGA Medical business will become part of the Cardiovascular Division of St Jude Medical.
Pursuant to the agreement and plan of merger and reorganisation, Asteroid Subsidiary Corporation, an indirect, wholly-owned subsidiary of St Jude Medical, merged with and into AGA Medical pursuant to a short-form merger completed using the procedures available under Delaware law.
St Jude Medical chairman, president and CEO Daniel Starks said that the addition of AGA Medical’s strong core business and innovative product pipeline will position St Jude Medical as the clear leader in the structural heart market and will help expand product portfolio for interventional radiology.